Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC – OncLive
OncLiveMutation Burden May Help Guide First-Line Immunotherapy in NSCLCOncLiveTumor mutational burden (TMB) in non–small cell lung cancer (NSCLC) identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab… Continue reading
